This is a StreetInsider.com Premium Only Page

Mirati Therapeutics (MRTX) –

Dec 6, 2023 08:30 AM Form DEFA14A Mirati Therapeutics,

Dec 1, 2023 04:44 PM Form DEFA14A Mirati Therapeutics,

Nov 24, 2023 04:46 PM Form 8-K Mirati Therapeutics, For: Nov 17

Nov 15, 2023 08:53 AM Form DEFA14A Mirati Therapeutics,

Nov 13, 2023 04:10 PM Form 8-K Mirati Therapeutics, For: Nov 10

Nov 10, 2023 07:31 AM Mirati Therapeutics (MRTX) Receives Positive Opinion from CHMP for KRAZATI

Nov 10, 2023 07:30 AM Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Fo

Nov 7, 2023 06:04 AM Leerink Partners Downgrades Mirati Therapeutics (MRTX) to Market Perform

Nov 6, 2023 04:49 PM Stifel Downgrades Mirati Therapeutics (MRTX) to Hold

Nov 6, 2023 08:05 AM Form 8-K Mirati Therapeutics, For: Nov 06

Nov 6, 2023 08:00 AM Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Nov 6, 2023 07:09 AM Form 10-Q Mirati Therapeutics, For: Sep 30

Nov 3, 2023 05:37 PM Mirati Therapeutics (MRTX) Approved by the MHRA for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation MRTXas

Nov 3, 2023 05:19 PM Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Nov 2, 2023 07:31 AM Kura Oncology (KURA) and Mirati Therapeutics (MRTX) Enter Collaboration and Supply Agreement to for KO-2806 and Adagrasib in KRAS-Mutated NSCLC

Nov 2, 2023 07:31 AM Form DEFM14A Mirati Therapeutics,

Nov 2, 2023 07:30 AM Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

Oct 23, 2023 05:32 PM Form PREM14A Mirati Therapeutics, For: Oct 23

Oct 20, 2023 09:01 AM MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb

Oct 20, 2023 09:01 AM MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb

Oct 17, 2023 06:03 PM Moore Kuehn Encourages SP, ORTX, MRTX, and SRT Investors to Contact Law Firm

Oct 17, 2023 04:00 PM Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)

Oct 13, 2023 06:01 AM Form DEFA14A Mirati Therapeutics,

Oct 12, 2023 01:08 PM Form SC 13D/A Mirati Therapeutics, Filed by: Boxer Capital, LLC

Oct 11, 2023 07:31 AM Form DEFA14A Mirati Therapeutics,

Oct 10, 2023 07:36 AM Form DEFA14A Mirati Therapeutics,

Oct 10, 2023 07:34 AM Form 8-K Mirati Therapeutics, For: Oct 08

Oct 10, 2023 07:31 AM Form DEFA14A Mirati Therapeutics,

Oct 10, 2023 06:49 AM Form DFAN14A Mirati Therapeutics, Filed by: BRISTOL MYERS SQUIBB CO

Oct 10, 2023 05:42 AM TD Cowen Downgrades Mirati Therapeutics (MRTX) to Market Perform

Oct 10, 2023 04:11 AM Increasing unusual option volume: RILY MRTX GRAB DFEN TPX UEC

Oct 10, 2023 01:46 AM Piper Sandler Downgrades Mirati Therapeutics (MRTX) to Neutral

Oct 9, 2023 09:46 AM Increasing unusual option volume: DFEN IMPP FRO ITA NAT INMD NEP KTOS CIM

Oct 9, 2023 08:54 AM Piper Sandler highlights 12 biotech takeover targets as M&A 'about as conducive as we've seen'

Oct 9, 2023 08:20 AM Walt Disney, Exxon, Lockheed Martin rise premarket; Spotify, Delta fall

Oct 9, 2023 06:48 AM B.Riley Downgrades Mirati Therapeutics (MRTX) to Neutral

Oct 9, 2023 06:47 AM B.Riley Downgrades Mirati Therapeutics (MRTX) to Neutral

Oct 9, 2023 06:35 AM Scotiabank Upgrades Mirati Therapeutics (MRTX) to Sector Perform

Oct 9, 2023 06:21 AM Bristol-Myers Squibb (BMY) to acquire Mirati (MRTX) in a deal worth up to $5.8 billion

Oct 9, 2023 06:05 AM Mirati Therapeutics (MRTX) PT Raised to $58 at JPMorgan

Oct 9, 2023 04:36 AM Jones Trading Downgrades Mirati Therapeutics (MRTX) to Hold

Oct 9, 2023 03:11 AM JMP Securities Downgrades Mirati Therapeutics (MRTX) to Market Perform

Oct 9, 2023 12:35 AM Jefferies Downgrades Mirati Therapeutics (MRTX) to Hold

Oct 8, 2023 08:31 PM Bristol Myers Squibb (BMY) to acquire Mirati Therapeutics (MRTX) for $58/share plus CVR

Oct 8, 2023 05:16 PM Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Oct 6, 2023 06:56 AM Mirati Therapeutics (MRTX) PT Raised to $72 at BMO Capital

Oct 6, 2023 05:00 AM Mirati Therapeutics (MRTX) PT Raised to $65 at B.Riley

Oct 6, 2023 04:15 AM Mirati Therapeutics (MRTX) PT Raised to $82 at JMP Securities

Oct 5, 2023 04:34 PM Form S-8 Mirati Therapeutics,

Oct 5, 2023 03:40 PM Mirati Therapeutics shares jump 38% as Sanofi said to explore acquisition